- Conditions
- Cancer
- Interventions
- rovalpituzumab tesirine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Duarte, California • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 1,571
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cystic Fibrosis
- Interventions
- VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 12
- States / cities
- Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more
- Conditions
- Smoking, Tobacco Use, Tobacco Smoking
- Interventions
- Product A, Product B, Product C, Product D, Product E, Product F, Product G, Product H
- Other
- Lead sponsor
- RAI Services Company
- Industry
- Eligibility
- 21 Years to 60 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- High Point, North Carolina
- Conditions
- Healthy
- Interventions
- Decitabine
- Drug
- Lead sponsor
- EpiDestiny, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Lymphoma, Large Cell, Diffuse
- Interventions
- Zevalin
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 34
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 31 more
- Conditions
- Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Interventions
- Rapidly generated virus specific T (R-MVST) cells
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
- Interventions
- Bridging radiation therapy, Liso-cel, Post-infusion radiation
- Radiation · Biological
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Blinatumomab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostatic Hyperplasia
- Interventions
- Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 2
- States / cities
- Evansville, Indiana • Austin, Texas
- Conditions
- Healthy Adult Participants
- Interventions
- Treatment A, Treatment B, Treatment C
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Healthy
- Interventions
- Hydromorphone Hydrochloride tablet 8 mg, Dilaudid® tablet 8 mg
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002
- U.S. locations
- 1
- States / cities
- Saint Charles, Missouri
- Conditions
- Healthy
- Interventions
- Seltorexant 40 mg, Seltorexant 20 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diet Modification, HDL, Inflammation
- Interventions
- Mediterranean Diet, Fast food diet
- Other
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 19 Years to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Davis, California
- Conditions
- Solid Tumor, Hematological Malignancies
- Interventions
- Belinostat, Atazanavir
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- B-Cell Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Glofitamab, Obinutuzumab (G), Rituximab (R), Tocilizumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Polatuzumab vedotin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Charlotte, North Carolina • Philadelphia, Pennsylvania
- Conditions
- Health Promotion
- Interventions
- Fun For Wellness (FFW)
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Coral Gables, Florida
- Conditions
- Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
- Interventions
- PF-08103402, Placebo, Midazolam
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 133 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Tuberculosis
- Interventions
- PA-824 200mg, PA-824 50mg
- Drug
- Lead sponsor
- Global Alliance for TB Drug Development
- Other
- Eligibility
- 19 Years to 50 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Bronchopulmonary Dysplasia
- Interventions
- Gastric Feeds, Jejunal Feeds
- Procedure
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 0 Hours to 1 Year
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
- Interventions
- Avelumab, Sunitinib
- Drug
- Lead sponsor
- Guru Sonpavde
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- RELiZORB, Placebo
- Device
- Lead sponsor
- Alcresta Therapeutics, Inc.
- Industry
- Eligibility
- 4 Years to 45 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Boise, Idaho • Indianapolis, Indiana + 8 more
- Conditions
- Healthy Participants
- Interventions
- Casdatifan
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Healthy Volunteers
- Interventions
- UCB0022
- Drug
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Multiple Myeloma, Secondary Immunodeficiency
- Interventions
- IGI, 10%
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 7
- States / cities
- Mobile, Alabama • Orange, California • Westwood, Kansas + 4 more